Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial

S. Sivaprasad; A.T. Prevost; J. C Vasconcelos; Riddell A; C Murphy; J Kelly; Bainbridge J; Rhiannon Tudor Edwards; David Hopkins; Philip Hykin

doi:10.1016/S0140-6736(17)31193-5

Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial

S. Sivaprasad
, A.T. Prevost
, J. C Vasconcelos
, Riddell A
, C Murphy
, J Kelly
, Bainbridge J
, Rhiannon Tudor Edwards
, David Hopkins
, Philip Hykin

National Institute for Health Research
Imperial College London
King's College London
University College London

Research output: Contribution to journal › Article › peer-review

251 Downloads (Pure)

Original language	English
Pages (from-to)	2193-2203
Journal	The Lancet
Volume	389
Issue number	10085
Early online date	7 May 2017
DOIs	https://doi.org/10.1016/S0140-6736(17)31193-5
Publication status	Published - 3 Jun 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S0140-6736(17)31193-5

2017 Clinical_efficacy_of_intravitreal_aflibercept_paperAccepted author manuscript, 407 KBLicence: CC BY-NC-ND

https://www.sciencedirect.com/science/article/pii/S0140673617311935Licence: Unspecified

Cite this

Sivaprasad, S., Prevost, A. T., Vasconcelos , J. C., A, R., Murphy, C., Kelly, J., J, B., Edwards, R. T., Hopkins, D., & Hykin, P. (2017). Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. The Lancet, 389(10085), 2193-2203. https://doi.org/10.1016/S0140-6736(17)31193-5

Sivaprasad, S. ; Prevost, A.T. ; Vasconcelos , J. C et al. / Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. In: The Lancet. 2017 ; Vol. 389, No. 10085. pp. 2193-2203.

@article{d69ecd23853948fe956a2f945be08619,

title = "Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial",

author = "S. Sivaprasad and A.T. Prevost and Vasconcelos, \{J. C\} and Riddell A and C Murphy and J Kelly and Bainbridge J and Edwards, \{Rhiannon Tudor\} and David Hopkins and Philip Hykin",

note = "The Efficacy and Mechanism Evaluation Programme, a Medical Research Council and National Institute for Health Research partnership.",

year = "2017",

month = jun,

day = "3",

doi = "10.1016/S0140-6736(17)31193-5",

language = "English",

volume = "389",

pages = "2193--2203",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier BV",

number = "10085",

}

Sivaprasad, S, Prevost, AT, Vasconcelos , JC, A, R, Murphy, C, Kelly, J, J, B, Edwards, RT, Hopkins, D & Hykin, P 2017, 'Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial', The Lancet, vol. 389, no. 10085, pp. 2193-2203. https://doi.org/10.1016/S0140-6736(17)31193-5

Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. / Sivaprasad, S.; Prevost, A.T.; Vasconcelos , J. C et al.
In: The Lancet, Vol. 389, No. 10085, 03.06.2017, p. 2193-2203.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial

AU - Sivaprasad, S.

AU - Prevost, A.T.

AU - Vasconcelos , J. C

AU - A, Riddell

AU - Murphy, C

AU - Kelly, J

AU - J, Bainbridge

AU - Edwards, Rhiannon Tudor

AU - Hopkins, David

AU - Hykin, Philip

N1 - The Efficacy and Mechanism Evaluation Programme, a Medical Research Council and National Institute for Health Research partnership.

PY - 2017/6/3

Y1 - 2017/6/3

U2 - 10.1016/S0140-6736(17)31193-5

DO - 10.1016/S0140-6736(17)31193-5

M3 - Article

SN - 0140-6736

VL - 389

SP - 2193

EP - 2203

JO - The Lancet

JF - The Lancet

IS - 10085

ER -

Sivaprasad S, Prevost AT, Vasconcelos JC, A R, Murphy C, Kelly J et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. The Lancet. 2017 Jun 3;389(10085):2193-2203. Epub 2017 May 7. doi: 10.1016/S0140-6736(17)31193-5